BBNX (Beta Bionics) LT-Debt-to-Total-Asset: 0.02 (As of Mar. 2026)


BBNX Beta Bionics Inc BBNX
10 GF Score
Price $17.20
! 3 Warning Signs
View Full Analysis

What is Beta Bionics LT-Debt-to-Total-Asset?

Beta Bionics BBNX +1.00% 10 LT-Debt-to-Total-Asset is 0.02 as of Mar. 2026. GuruFocus rates BBNX with a GF Score™ of 10/100. The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Beta Bionics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.02.

Beta Bionics's long-term debt to total assets ratio increased from Mar. 2025 (0.02) to Mar. 2026 (0.02). It may suggest that Beta Bionics is progressively becoming more dependent on debt to grow their business.

Beta Bionics  (NAS:BBNX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Beta Bionics LT-Debt-to-Total-Asset Related Terms

Beta Bionics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Beta Bionics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beta Bionics LT-Debt-to-Total-Asset Chart

Beta Bionics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
0.09 0.03 0.04 0.02

Beta Bionics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.02 0.02 0.02
BBNX
10GF Score
Beta Bionics Inc BBNX
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beta Bionics LT-Debt-to-Total-Asset Calculation

Beta Bionics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=5.365/328.743
=0.02

Beta Bionics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=5.073/304.417
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.02 mean?
Beta Bionics (BBNX) has a LT-Debt-to-Total-Asset of 0.02 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Beta Bionics and its competitors.
Is Beta Bionics' LT-Debt-to-Total-Asset too high?
Beta Bionics' current LT-Debt-to-Total-Asset is 0.02. Overall, Beta Bionics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Beta Bionics' LT-Debt-to-Total-Asset compare to CBLL and SIBN?
Beta Bionics' LT-Debt-to-Total-Asset of 0.02 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?
A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Beta Bionics and its competitors. Beta Bionics's current LT-Debt-to-Total-Asset is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Bionics stock overvalued right now?
Beta Bionics (BBNX) has a current LT-Debt-to-Total-Asset of 0.02. The current LT-Debt-to-Total-Asset is 0.02. Beta Bionics' overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Beta Bionics (BBNX), the current LT-Debt-to-Total-Asset is 0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beta Bionics Business Description

Address 11 Hughes, Irvine, CA, USA, 92618
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
10GF Score

Get the complete analysis for BBNX

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.20
Price